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Abstract.  Ng-CAM and N-CAM are cell adhesion 
molecules (CAMs), and each CAM can bind 
homophilically as demonstrated by the ability of 
CAM-coated beads (Covaspheres)  to self-aggregate. 
We have found that the extent of aggregation of 
Covaspheres coated with either Ng-CAM or N-CAM 
was strongly inhibited by the intact 1D1  and 3F8 
chondroitin sulfate proteoglycans of rat brain, and by 
the core glycoproteins resulting from chondroitinase 
treatment of the proteoglycans. Much higher concen- 
trations of rat chondrosarcoma chondroitin sulfate pro- 
teoglycan (aggrecan)  core proteins had no significant 
effect in these assays.  The 1D1  and 3F8 proteoglycans 
also inhibited binding of neurons to Ng-CAM when 
mixtures of these proteins were adsorbed to polysty- 
rene dishes. 
Direct binding of neurons to the proteoglycan core 
glycoproteins from brain but not from chondrosarcoma 
was demonstrated using an assay in which cell- 
substrate contact was initiated by centrifugation, and 
neuronal binding to the 1D1 proteoglycans was 
specifically inhibited by the 1D1  monoclonal antibody. 
Different forms of the 1D1 proteoglycan have been 
identified in developing and adult brain.  The early 
postnatal form (neurocan) was found to bind neurons 
more effectively than the adult proteoglycan, which 
represents the C-terminal half of the larger neurocan 
core protein. Our results therefore indicate that certain 
brain proteoglycans can bind to neurons, and that Ng- 
CAM and N-CAM may be heterophilic ligands for 
neurocan and the 3F8 proteoglycan. The ability of 
these brain proteoglycans to inhibit adhesion of cells 
to CAMs may be one mechanism to modulate cell 
adhesion and migration in the nervous system. 
T 
nEl~.  is increasing evidence to indicate that glycos- 
aminoglycans  and  proteoglycans  are  involved  in 
modulating cell interactions in developing nervous tis- 
sue. In some of the initial studies in this area it was found 
that  soluble  glycosaminoglycans  or  glycosaminoglycan- 
coated substrata modify the adhesion and neurite extension 
of cultured PC12 cells (Akeson and Warren,  1986; Damon 
et al.,  1988) and dorsal  root ganglia  (Carbonetto  et al., 
1983; Verna et al., 1989). More recent studies indicate that 
chondroitin sulfate and keratan sulfate proteoglycans may be 
components of barriers  for axonal migration  (Snow et al., 
1990a, b,  1991; McKeon et al.,  1991; Oakley and Tosney, 
1991; Cole and McCabe, 1991; Brittis et al., 1992), and that 
chondroitin/keratan  sulfate proteoglycans can inhibit neural 
crest cell migration (Perris and Johansson,  1990). In addi- 
tion, studies of spatial and temporal changes in the distribu- 
tion of proteoglycans during avian neural crest development 
showed that  in  general,  chondroitin/keratan  sulfate  pro- 
teoglycans are abundant in regions where neural crest cells 
are absent,  and that their segmental distribution  inversely 
correlates  with migration  pathways of neural  crest  cells 
(Perris et al.,  1991). 
Although there is in certain cases a degree of chemical 
specificity for the effects observed in vitro, it is not clear to 
what extent they are due to factors such as modification of 
the surface charge of the substrate, alteration of the binding 
of growth promoting  or extracellular  adhesive  molecules 
produced by the cultures, or a modulation of binding medi- 
ated  by  cell  adhesion  molecules  (CAMs)  1 in the plasma 
membrane. In tissues, sulfated glycosaminoglycans occur as 
covalent complexes with a core protein in the form of pro- 
teoglycans  (Margolis  and  Margolis,  1989), and  both  the 
glycosaminoglycan and protein components have been sug- 
gested to affect cell behavior (Perris and Johansson,  1990; 
Snow et al.,  1990b, 1991; Brittis et al.,  1992). 
Other cell surface molecules that have been implicated in 
adhesion during neural development include various CAMs 
that are members of the Ig superfamily (reviewed in Edel- 
man,  1987; Grumet,  1991; Rathjen  and  Jessel,  1991). 
N-CAM and Ng-CAM are two of the CAMs that are  ex- 
pressed  on neurons  and have been  implicated  in various 
aspects of cell adhesion, cell migration, and neurite fascicu- 
lation that correlate with their general patterns of  expression 
during  development  (Edelman  and  Cunningham,  1990; 
Rutishauser,  1991; Walsh and  Doherty,  1991; Grumet, 
1992). Each CAM can mediate homophilic binding (Hoff- 
man and Edelman,  1983; Grumet and Edelman,  1988) and 
1.  Abbreviations  used  in  this  paper:  CAM,  cell  adhesion  molecule; 
N-CAM, neural CAM; Ng-CAM, neuron-glia  CAM. 
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met, M., and G. M. Edelman, 1992.  Soc. Neurosc. Abstr. 
18:1326). Although these neural CAMs are functionally and 
structurally distinct, they share features including certain 
carbohydrate structures (Grumet et al.,  1984a),  and both 
contain related Ig-like and fibronectin-like domains (Cun- 
ningham et al.,  1987; Burgoon et al.,  1991). 
In view of evidence that extracellular proteoglycans may 
act as  repulsive molecules which modulate cell-cell  and 
cell-matrix  interactions,  it  is  important  to  determine 
whether purified brain proteoglycans can affect the behavior 
of brain cells and, in particular, interfere with mechanisms 
of cell adhesion. Recently, the biochemical properties and 
immunocytochemical localization of five developmentally 
regulated chondroitin sulfate proteoglycans of brain have 
been characterized using specific mAbs, and one of  these has 
been cloned and its primary structure determined (Rauch et 
al.,  1991, 1992).  To study the potential roles of individual 
proteoglycans in nervous tissue histogenesis, we have exam- 
ined the ability of two of these proteoglycans,  1D1  (now 
named neurocan; Rauch et al., 1992) and 3F8, to affect inter- 
actions of N-CAM and Ng-CAM, and have compared their 
effects to those of a nonnervous tissue (rat chondrosarcoma) 
chondroitin sulfate proteoglycan (aggrecan). In addition to 
affecting CAM binding, we found that the brain proteogly- 
cans supported binding of neurons and perturbed cell adhe- 
sion to Ng-CAM. 
Materials and Methods 
Proteins and Antibodies 
Ng-CAM and N-CAM were purified from 14-d embryonic chicken brains 
by immunoaffinity chromatography using specific mAbs (Grumet and Edel- 
man, 1988).  Analysis of the proteins on SDS-PAGE showed that Ng-CAM 
consisted of a major component of 135 kD and lesser amounts of the 200 
and 80 kD species (Grumet and Edelman, 1988),  and N-CAM migrated as 
beterodisperse species above 120 kD as described previously (Hoffman et 
al.,  1982). 
Chondroitin sulfate proteoglycans were extracted with PBS  from the 
brains of 7-d or 2- to 3-mo-old Sprague Dawley rats, and purified by ion 
exchange chromatography and gel filtration (Kiang et al.,  1981). The 1D1 
and 3F8 proteoglycans were then isolated by immunoaflinity chromatogra- 
phy using mAbs coupled to CNBr-activated Sepharose 4B (Rauch et al., 
1991).  Analysis of the proteins on SDS-PAGE after chondroitinase treat- 
ment showed that the 1D1 proteoglycan from adult brain contained a 150-kD 
core glycoprotein, whereas the 1D1 proteoglycan from 7-d brain showed an 
additional major band at 245 kD.  Because the COOH-terminal half of the 
proteoglycan which can be isolated from adult brain with the 1D1 mAb is 
not the only neurocan-derived proteoglycan present at this age, we will refer 
to this as the adult 1D1 proteoglycan, and reserve the designation of neuro- 
can for the larger form of the proteoglycan found in early postnatal brain. 
In both cases, the 1D1 proteoglycan was accompanied by a 45-kD link pro- 
tein (identified with the 8A4 mAb; Caterson et al., 1985).  The core glyco- 
protein obtained by chondroitinase treatment of the 3F8 proteoglycan from 
either early postnatal or adult brain migrated on SDS-PAGE as a single band 
at 400 kD (Rauch et al., 1991). Chondroitin sulfate proteoglycan aggregates 
(containing hyaluronic acid and link protein) were also extracted from a 
transplantable rat chondrosarcoma (Choi et al., 1971), and isolated by CsC1 
density gradient centrifugation (Faltz et al.,  1979). 
For studies of the core proteins, proteoglycans were digested for 45-60 
rain at 37~  with protease-free chondroitinase ABC (Seikagaku  America 
Inc., Rockville, MD) in 100 mM Tris-HCl buffer (pH 8.0 at 37~  contain- 
ing 30 mM sodium acetate. Ratios of  0.5 and 1.5 mU chondroitinase//~g pro- 
teoglycan protein were used for the 1D1  and 3F8 proteoglycans, respec- 
tively,  whereas the chondrosarcoma proteoglycan, which contains a much 
higher  concentration  of  chondroitin  sulfate,  was  digested  with  chon- 
droitinase in a ratio of 4 mU/ttg dry weight. Completeness of digestion was 
confirmed by SDS-PAGE, which demonstrated that the large native pro- 
teoglycan which did not enter the separating gel was converted to discrete 
core glycoprotein bands after enzyme treatment (Rauch et al.,  1991). 
To test the sensitivity of proteoglycans to proteolysis, solutions contain- 
ing 0.1 mg/ml proteoglycan were treated with 10 #g/ml of trypsin for 1 h 
at 37~  and the reaction was terminated by addition of 20/zg/ml of soybean 
trypsin inhibitor. 
Polyclonal rabbit antibodies against chicken Ng-CAM were prepared as 
previously described (Grumet et al., 1984b).  mAbs specific for the ID1 and 
3F8 proteoglycans have previously been described (Rauch et al., 1991), and 
the Ig fraction was obtained after precipitation with ammonium sulfate at 
45%  of saturation. 
Other proteins included Engelbreth-Holm-Swarm laminin (Collabora- 
tive Research, Bedford, MA), human plasma fibronectin (New York Blood 
Center,  New  York,  NY),  BSA  (ICN  Biomedical,  Lisle,  IL),  and  de- 
oxyribonuclease I (Worthington Biochemical Corp., Freehold, NJ). 
Covasphere Aggregation 
Proteins (50 ~g) were covalently coupled to 200/~l of 0.5-/~m Covaspheres 
(Duke Scientific Corp., Palo Alto, CA), washed twice in PBS containing 
1 mg/ml BSA/10  mM NAN3, and resuspended in the original volume of 
buffer (200 ~l) (Grumet and Edelman, 1988);  Covaspheres as supplied by 
the  manufacturer  were at  a  concentration of 850-cm  2 surface  area/ml. 
Quantitative measurements indicated that under these conditions ,x,20% of 
the Ng-CAM protein was hound to the Covaspheres. For Covasphere aggre- 
gation experiments, pre-existing aggregates in the bead preparations were 
first dissociated by sonication for 10-20  s, and 6-/tl aliquots (containing 
•0.3/zg  of protein) were mixed with 54 #l of PBS containing the indicated 
amounts of proteins. After a 30-min incubation on ice, the samples were 
resonicated and aggregation was monitored at 25~  The appearance of su- 
perthreshold aggregates of Covaspheres was  measured  using a  Coulter 
Counter (model ZF) fitted with a  100-/xm aperture, set at amplification = 
0.17, aperture current =  0.33, threshold 10-100;  these settings allowed de- 
tection of  particles >,'~4 #m as described previously (Grumet and Edelman, 
1988; Hoffman and Edelman, 1987).  Superthreshold aggregates were mea- 
sured in samples of 20 p.1 that were diluted into 20 ml of PBS. Microscopic 
observations of Covasphere preparations that had been measured in the 
Coulter Counter indicated that populations containing aggregates of 5-10 
Covaspheres were subthreshold, inasmuch as they gave measurements that 
were not significantly greater than the background levels for buffer alone 
(range of 300-1,000).  It was difficult to resolve the numbers of individual 
Covaspheres present in larger aggregates. 
Gravity Cell  Binding Assay 
Neurons were prepared from 9-d chicken embryo brains (Grumet and Edel- 
man,  1988)  and cell binding to protein-coated substrates was performed 
using a gravity assay (Friedlander et al., 1988).  Briefly, 2 #1 of proteins in 
PBS were placed in a circular array near the center of a polystyrene petri 
dish. After 30 min, the dishes were washed three times with PBS containing 
1 mg/ml BSA. After 1-h incubation, ~he BSA-blocking solution was removed 
and replaced with 2  ￿  106 cells in 0.5  ml of Eagle's minimal essential 
medium with spinner salts (Gibco Laboratories, Grand Island, NY) con- 
taining 50/~g/ml deoxyribonuclease I, and incubated for 1 h at 37~  The 
unbound cells were removed by four gentle washes in PBS and a fifth wash 
in medium; in some experiments, the cells were fixed with 1% glutaralde- 
hyde. The dishes were observed by phase contrast microscopy, and cells 
were counted in four fields (2.2 mm  2) within the protein-coated area. 
Centrifugation Cell Binding Assay 
Proteins were adsorbed for 1 h to U-shaped wells of 96-well polyvinyl chlo- 
ride microtiter plates,  which were then washed, and blocked with BSA 
(Friedlander et al., 1988).  200/~1 of a cell suspension containing 5  x  104 
cells was placed in each well and the plate was centrifuged at "~  g for 
2 min at room temperature. The pattern of cells in each well was observed 
under dark field illumination (Friedlander et al.,  1988),  and reflects a bal- 
ance between the centrifugal force and the adhesivity of the substrate. On 
nonadhesive substrates, the cells were centrifuged into a pellet at the bottom 
of the well, and as the adhesivity of the substrate increased, more cells 
bound to the substrate along the wall of the well which could be detected 
in a circular area with a measurable diameter. On strongly adhesive sub- 
strates, cells were distributed more or less uniformly on the well (see 
Fig. 9). 
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After  gravity binding  assays, dishes were  treated  with  3.7%  formalde- 
hyde/PBS and 0.1 M glycine/PBS, each for 10 min. After blocking for 30 
min in PBS containing 4% goat serum, indirect staining (Grumet et al., 
1984b) was performed  in the same  buffer  by sequentially  treating for 30 min 
with 0.1 mg/ml  of rabbit Ig, and 1:100 dilution of fluorescein-labeled  goat 
anti-rabbit Ig. The dishes were visualized under a Nikon Diaphot micro- 
scope equipped for fluorescence  and photographed  using an N2000 camera 
(Nikon Instruments, Garden City, NY). 
Analytical Methods 
Proteins were resolved on SDS-PAGE (Laemmli,  1970)  and were either 
transferred to nitrocellulose and immunoblotted with antibodies (Grumet et 
al.,  1984b; Towbin et al.,  1979) or stained with Coomassie blue. Protein 
was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, 
Richmond, CA). 
Results 
Inhibition of CAM-Covasphere Aggregation 
by Proteoglycans 
In previous studies, it was found that Ng-CAM (Grumet and 
Edelman, 1988) and N-CAM (Hoffman and Edelman, 1983) 
individually  mediated  homophilic  binding  when  recon- 
stituted into liposomes or when covalently bound to the sur- 
face of beads (Covaspheres). The rate of aggregation of Ng- 
CAM-Covaspheres was measured using a Coulter Counter 
to detect aggregates larger than a given size and was shown 
to be highly dependent on the concentration of Covaspheres 
in suspension. It was previously determined that at a concen- 
tration of ~85 cm  2 of bead surface area/ml, the appearance 
of aggregates began to reach a plateau level after ~1 h of in- 
cubation  (Grumet and Edelman,  1988).  Therefore,  to ex- 
plore  potential  interactions  between  proteoglycans  and 
CAMs, we used this concentration of beads to test the effects 
of various proteins and proteoglycans on the extent of aggre- 
gation of Ng-CAM-Covaspheres after 2  h of incubation. 
The appearance of aggregates of fluorescent Covaspheres 
was observed by fluorescence microscopy and was quanti- 
tated using a Coulter Counter (see Materials and Methods). 
Whereas control proteins including BSA and fibronectin did 
not inhibit aggregation of the Ng-CAM-coated beads (Gru- 
met and Edelman,  1988),  two distinct chondroitin  sulfate 
proteoglycans from 7-d postnatal rat brain inhibited aggrega- 
tion (Fig. 1). The aggregation of Ng-CAM-Covaspheres was 
inhibited in a concentration-dependent manner by neurocan 
(1D1) and the 3F8 proteoglycan (Fig.  1). In contrast, aggre- 
can, a rat chondrosarcoma chondroitin sulfate proteoglycan 
(Doege et al., 1987), did not inhibit the aggregation (Fig. 1), 
suggesting that the effects were not simply related to the pres- 
ence of chondroitin sulfate. This conclusion was further sup- 
ported by the finding that the core glycoproteins (open sym- 
bols)  obtained  by  chondroitinase  treatment  of the  native 
proteoglycans (filled symbols) were approximately as effec- 
tive in inhibiting the aggregation of Ng-CAM-Covaspheres 
(Fig. 1). Moreover, most of the inhibitory activity was elimi- 
nated  after  treating  the  proteoglycans  with  trypsin  (see 
Materials and Methods). These results demonstrate that the 
effects of neurocan and the 3F8 proteoglycan on Ng-CAM 
binding are not mediated by the glycosaminoglycan chains, 
but that a protein domain (or possibly a cluster of oligosac- 
charides present on the proteoglycan core protein) is involved. 
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Figure I.  Effects of proteoglycans  on aggregation of Ng-CAM- 
Covaspheres. The appearance of superthreshold aggregates of Cova- 
spheres  coated  with  Ng-CAM  was measured  after 2 h  using  a 
Coulter counter. 6-/zl samples of Ng-CAM-Covaspheres were mixed 
in a final volume of 60 #1 PBS in the presence of various concentra- 
tions of native proteoglycans (PG,  ) and proteoglycan core pro- 
teins obtained by chondroitinase treatment (Chase, -  ....  );  1D1 ([], 
-) and 3F8  (o,  e) proteoglycans  from 7-d brain,  and rat chon- 
drosarcoma aggrecan (z,, A). Data represent means (n =  3) +  the 
standard error of the percent of the control levels of superthreshold 
aggregates detected.  The mean level of superthreshold  particles 
in control  Samples was  32,582  +  788. (--l-)  1D1  PG  -Chase; 
(---[]---) 1D1 PG +Chase; (--e-) 3F8 PG -Chase; (---o---) 3F8 PG 
+Chase; (-i-) Aggrecan  -Chase; (--~---)Aggrecan +Chase. 
Based on these results and the possible complications due to 
the presence of highly charged glycosaminoglycans on the 
native proteoglycans, we focused primarily on effects pro- 
duced by the chondroitinase-treated proteoglycans. 
The  3F8  proteoglycan  inhibited  aggregation  of  Ng- 
CAM-Covaspheres both at 10 and 30/zg/ml (Fig, 2 b). The 
1D1 proteoglycan from 7-d rat brain also strongly inhibited 
aggregation at  10/~g/ml  (Fig.  2  c).  However, at 30/zg/ml 
some aggregation could be detected by fluorescence micros- 
copy (Fig. 2 d) and using the Coulter Counter (Fig.  3).  In 
contrast to the fairly uniform effects on aggregation of Ng- 
CAM-Covaspheres in the presence of the 3F8 proteoglycan, 
the effects of the 7-d 1D1 proteoglycan at 30/~g/ml were much 
more heterogeneous; for example, microscopic observations 
showed that in addition to single Ng-CAM-Covaspheres and 
small aggregates (Fig. 2 d), large aggregates were also de- 
tected in some experiments (data not shown). This effect of 
the 7-d 1D1 proteoglycan was somewhat variable between ex- 
periments and increased with time. In certain experiments, 
measurement of superthreshold aggregates showed little or 
no difference between the 7-d 1D1 and 3F8 proteoglycans at 
2 h of incubation but large aggregates were observed after 
24 h of incubation with the chondroitinase-treated 1D1 pro- 
teoglycan but not with the other brain proteoglycans tested, 
which showed persistent inhibition (Table I, and microscopic 
observations, data not shown). These effects may be related 
to the ability of the 7-d 1D1 proteoglycan to self-aggregate 
(see Discussion). It is also important to note that the counter 
detects particles larger than a certain size but does not pro- 
vide a weighted average that would be needed to determine 
the  percentage of Covaspheres present  in  the  aggregates. 
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Covaspheres.  Green-fluorescing  Ng-CAM-Covaspheres after in- 
cubation for 2 h at 25~  in the presence of 10 #g/ml ofBSA (a), 
30 #g/ml 3F8 proteoglycan (b), 10 #g/ml 7-d 1D1 proteoglycan (c), 
30 #g/ml 7-d 1D1 proteoglycan (d), 30 #g/ml adult 1DI proteogly- 
can (e),  and 80 #g/ml aggrecan (f), were photographed  under  a 
fluorescence microscope as described  in Materials  and Methods. 
In contrast to the adult  1D1 and the 7-d 3F8 proteoglycans which 
strongly inhibited the aggregation at 30 #g/ml, we observed that the 
size distribution of  aggregates varied considerably when the 7-d 1D1 
proteoglycan was tested at 30 #g/ml, and panel d represents a typi- 
cal sample. Bar, 100 #m. 
Therefore,  in  this mode of operation the  Coulter Counter 
may provide an indication of aggregation that is an underesti- 
mate of the percentage of Covaspheres in aggregates, partic- 
ularly when larger aggregates have formed. 
Different  forms of the  1D1  proteoglycan are  present  in 
early postnatal and adult brain (Rauch et al.,  1991),  and the 
adult  form showed dose-dependent  inhibition  when tested 
over a  range of concentrations  (Fig.  3).  Unlike  the  early 
postnatal form of this proteoglycan, the adult form did not 
potentiate aggregation of Ng-CAM-Covaspheres when tested 
at 30 #g/ml (Figs. 2 e, and 3). In contrast to the brain pro- 
teoglycans, aggrecan had no effect on the Ng-CAM-Cova- 
spheres even when tested at concentrations up to 80 #g/ml 
(Fig.  2 f).  It is  unlikely  that  the  proteoglycans  inhibited 
Covasphere aggregation by a trivial mechanism such as pro- 
teolysis of Ng-CAM because we found that incubation of the 
1D1  and 3F8 proteoglycans with Ng-CAM for 1 h at 37~ 
had no effect on the molecular sizes of the Ng-CAM compo- 
nents when resolved by SDS-PAGE (data not shown). 
To determine whether the proteoglycans could affect other 
CAMs, a similar series of experiments was performed using 
N-CAM-coated beads.  The aggregation of N-CAM-Cova- 
spheres was inhibited strongly in the presence of 3 #g/ml of 
the native 1D1 and 3F8 proteoglycans (Fig. 4).  In contrast, 
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Figure 3. Effects of chondroitinase-treated  1D1 brain proteoglycans 
on aggregation of  Ng-CAM-Covaspheres. The appearance of super- 
threshold  aggregates of Covaspheres  coated  with  Ng-CAM was 
measured after 2 h using a Coulter counter. 6-#1 samples of Ng- 
CAM-Covaspheres  were mixed in a final volume of 60 #1 PBS in 
the presence  of various concentrations  of chondroitinase-treated 
proteoglycan  core  proteins.  1D1  proteoglycan  from 7-d (t2) and 
adult (<5) brain, and rat chondrosarcoma aggrecan (zx). Data repre- 
sent means (n = 4) + the standard error of the percent of the con- 
trol levels of superthreshold  aggregates detected.  The mean level 
of superthreshold particles in control samples was 25,971 + 2,020. 
native aggrecan had little or no effect at the same concentra- 
tion but showed some inhibition when tested at higher con- 
centrations  (Fig.  4).  The observation that native aggrecan 
could inhibit aggregation of Covaspheres coated with N-CAM 
but did not affect Covaspheres coated with Ng-CAM (Fig.  1) 
may be attributed to electrostatic interactions between nega- 
tively charged  polysialic  acid  on  N-CAM  and  negatively 
charged sulfate and uronic acid residues on aggrecan chon- 
droitin sulfate. This possibility is consistent with the observa- 
tions  that  chondroitinase-treated  aggrecan  did  not  inhibit 
aggregation of N-CAM-Covaspheres (Fig.  5).  In addition, 
chondroitinase trealment did not significantly  modify the inhib- 
itory effects of the 1D1 and 3F8 brain proteoglycans (Fig. 5). 
The inhibitory effects of the 1D1 and 3F8 proteoglycans on 
the  aggregation  of Ng-CAM-  and  N-CAM-coated  beads 
Table I. Effects of  High Concentrations of  Proteoglycans 
on Aggregation of  Ng-CAM Covaspheres 
Chondroitinase 
Proteoglycan  treatment  Superthreshold  aggregates 
(2 h)  (24 h) 
None  -  34,860  +  2,789  32,765  +  343 
Neurocan  -  356  +  233  273  +  67 
Neurocan  +  434  +  144  3,519  +  286 
7-d  3F8  -  494  +  130  532  +  193 
7-d 3F8  +  459  5:23  592  5:57 
Ng-CAM-Covaspheres (6 #1 in a final volume of 60 #1) were preincubated  for 
15  rain on ice with untreated  or chondroitinase-treated  protr  at 30 
#g/rnl, sonicated,  and the appearance  of superthreshold  aggregates was mea- 
sured at the times indicated using a Coulter Counter as described in Materials 
and Methods.  Numbers of superthreshold  aggregates  are averages of duplicates 
+  mean deviations. 
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Figure 4. Inhibition of N-CAM-Covasphere  aggregation by native 
brain proteoglycans. The appearance of superthreshold aggregates 
of Covaspheres coated with N-CAM was measured after 2 h;  1D1 
proteoglycan  from 7-d brain (m), 3F8 proteoglycan from 7-d brain 
(e), and rat chondrosarcoma  aggrecan (,t). Data represent means 
(n  =  3)  •  the standard error of the percent of the control levels 
of superthreshold  aggregates detected.  The mean level of super- 
threshold  particles  in control  samples was 25,622 •  2,651. 
were maximal at ,'o3-10 #g/ml. In a typical assay (60 gl) at 
this  concentration  of proteoglycans,  the  amount  of pro- 
teoglycan in solution was ~0.2-0.6 gg and the amount of Ng- 
CAM on the Covaspheres was ,',,0.3  gg (see Materials and 
Methods),  suggesting that the brain proteoglycans can per- 
turb  homophilic CAM binding  at approximately stoichio- 
metric levels with the CAM.  In contrast,  aggrecan had no 
significant effect at several fold higher concentrations (Figs. 
2,  3,  and 5). 
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Figure 5. Inhibition  of N-CAM-Covasphere  aggregation by chon- 
droitinase-treated  brain proteoglycans. The appearance  of super- 
threshold  aggregates  of Covaspheres  coated  with  N-CAM  was 
measured after 2 h of incubation with chondroitinase-treated  pro- 
teoglycans (PG). Data represent means (n =  3) + the standard er- 
ror of the percent of the control levels of superthreshold aggregates 
detected.  The mean level of superthreshold  particles  in control 
samples was 19,993 •  2,190. (-0-) 7<11D1 PG; (-<>-)  7-d 3F8 PG; 
(-~-) Adult 1D1 PG; (-~-) Aggrecan. 
Figure 6. Binding of neurons to substrates coated with mixtures of 
Ng-CAM  and  chondroitinase-treated  proteoglycans,  and  im- 
munofluorescent staining for Ng-CAM. Attachment of neurons to 
dishes coated with mixtures containing 30 gg of Ng-CAM and 30 
gg of aggrecan (a and b) or 30/zg of Ng-CAM and 30 gg of neuro- 
can (c and d); a and c are phase contrast photomicrographs of  fields 
corresponding  to those  shown  in the  immunofluorescence  pho- 
tomicrographs (b and d, respectively) obtained by staining with 0.1 
mg/rni of  polyclonal antibodies against Ng-CAM. Note that in addi- 
tion to staining of the substrate, in b many neurons and cell debris 
were also stained by the anti-Ng-CAM  antibodies.  Bar, 100 #m. 
Neuronal Adhesion to Ng-CAM Is Inhibited in the 
Presence of  Proteoglycans 
To determine whether the brain proteoglycans could affect 
cell adhesion,  we tested the binding of cells to substrates 
containing mixtures of CAMs and various chondroitinase- 
treated  proteoglycans.  Although  substrate  bound  N-CAM 
weakly promoted cell adhesion, the 8D9 antigen (Ng-CAM) 
was  found  to  be a  potent promoter of neuronal  adhesion 
(Lagenaur and Lemmon, 1987). We obtained similar results 
(data not shown),  and Ng-CAM was therefore used in the 
present studies. When mixtures containing equal amounts of 
Ng-CAM and aggrecan were adsorbed to petri dishes, bind- 
ing of neurons could be detected, but much lower levels of 
binding were detected when equivalent amounts of neurocan 
were used (Fig. 6, a and c). To verify that the proteoglycans 
were not simply preventing the binding of Ng-CAM to the 
substrates, the dishes were immunofluorescently stained for 
Ng-CAM after the binding assay. Ng-CAM was detected in 
regions adsorbed with mixtures containing aggrecan (Fig. 6 
b) or neurocan (Fig. 6 d), as well as with mixtures contain- 
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the presence of native brain proteoglycans.  Attachment of neurons 
prepared from 9-d chicken embryo brains to dishes  coated with 
mixtures  containing 10/zg/ml of Ng-CAM and  10/zg/ml of pro- 
teoglycans was measured in gravity binding assays as described in 
Materials  and Methods.  Data represent  means (n =  4) +  the stan- 
dard error of ceils  bound to 2.2 mm  2 of the dish. 
ing the 3F8 proteoglycan and the adult brain 1D1 proteogly- 
can  (data  not  shown).  Preliminary  experiments  also  indi- 
cated that when Ng-CAM was first adsorbed to dishes and 
proteoglycans were then  applied,  neurocan  inhibited  neu- 
ronal binding whereas aggrecan had little or no effect. 
To analyze the relative effectiveness of the different pro- 
teoglycans, the binding of neurons to mixtures, of Ng-CAM 
and various proteoglycans was measured using different ra- 
tios of  proteoglycan to Ng-CAM. When equal amounts of  na- 
tive (non-chondroitinase-treated) proteoglycans were mixed 
with Ng-CAM and adsorbed to petri dishes,  aggrecan pro- 
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Figure 8. Binding of neurons to Ng-CAM substrates  is inhibited  in 
the presence of  chondroitinase-treated  brain proteoglycans.  Attach- 
ment of  neurons prepared from 9-d chicken embryo brains to dishes 
coated with mixtures containing a final concentration of 10 #g/ml 
of Ng-CAM and the indicated  amounts  of chondroitinase-treated 
1D1 proteoglycan from 7-d ([2) and adult brain (<>), 3F8 proteogly- 
can from 7-d brain (o), and rat chondrosarcoma aggrecan (zx) was 
measured in gravity binding assays as described in Materials  and 
Methods.  Data represent  means (n  =  4) +  the standard error of 
cells  bound to 2.2 mm  2 of the dish. 
Figure 9. Binding of neurons to proteins in the centrifugation  assay. 
Substrates  in 96-weU plates  were prepared by incubation  with the 
indicated concentrations of different proteins.  Neurons were added 
to the wells and binding was performed as described in Materials 
and Methods.  The wells were visualized  by dark field microscopy 
using a 4￿  objective  and the cells  appeared as bright spots.  The 
speckled  pattern  of cells  on  Ng-CAM-coated wells  represents 
strong binding to the substrate,  whereas  the cells formed pellets at 
the bottom of BSA-coated wells, indicating a lack of binding to the 
well.  The arrow in the panel representing  treatment with 5 #g/ml 
of adult ID1 proteoglycan indicates the diameter of the binding re- 
gion (see  Table  II).  All proteoglycans were treated  with  chon- 
droitinase.  Bar, 0.35 mm. 
duced a relatively small inhibition of neuronal binding (Fig. 
7). In contrast, equivalent amounts of neurocan and the 3F8 
proteoglycan strongly  inhibited  (>80%)  neuronal  binding 
(Fig. 7). In similar experiments using chondroitinase-treated 
aggrecan, little or no effect on neuronal binding was detected 
(Fig. 8), suggesting that the high concentration of chondroi- 
tin sulfate in aggrecan as compared to the brain proteogly- 
cans may make native aggrecan an inappropriate control in 
certain assays.  To avoid the potential complications due to 
the presence of chondroitin sulfate, we focused on compari- 
sons between the proteoglycan core proteins. When mixtures 
containing 10 #g/ml of Ng-CAM and various concentrations 
of proteoglycan were adsorbed to dishes,  the  1D1 and 3F8 
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Substrates in the Centrifugation Assay 
Protein applied 
(izg/ml) 
2.5  5  10  20 
7-d  1D1  1.07  :t: 0.15 
7-d 3F8  0.18  +  0.08 
Adult 1D1  0.33 5:0.15 
Aggrecan  0.15 5:0.15 
Ng-CAM  >2.5 
BSA  0.18 5:0.08 
Diameter (nun) 
1.80  5:0.25  1.95  +  0.25  >2.5 
1.20  +  0.08  2.33  +  0.15  >2.5 
0.68 + 0.08  1.13 + 0.13  1.08 + 0.15 
0.13 + 0  0.05 + 0.05  0.05 +  0.05 
>2.5  >2.5  >2.5 
0.20 + 0.20  0.03 +  0.03  0 
Centrifugation assays were performed after incubating 96-well plates with pro- 
tein solutions at the concentrations indicated, as described in the legend to Fig. 
9. The diameter in millimeters of the binding region (for example, see diagonal 
arrow in Fig. 9, adult 1D1 at 5 /zg/ml) was measured under the microscope 
using an internal calibrated reticle; the mean diameters and the standard errors 
were calculated for triplicate samples. All proteoglycans were treated with 
chondroitinase. Diameters >2.5  mm were difficult  to  resolve because they 
represented binding along the near vertical sides of the U-shaped wells. 
proteoglycans produced concentration-dependent inhibition 
of neuronal binding (Fig. 8). Although all of the brain pro- 
teoglycans inhibited strongly when applied at 10/~g/ml, the 
1D1 proteoglycan from 7-d brain was slightly more effective 
than the adult form at equivalent concentrations. In contrast 
to the ability of the brain proteoglycans to inhibit neuronal 
adhesion to substrates prepared using mixtures containing 
Ng-CAM, preliminary experiments indicated that these pro- 
teoglyeans had little or no effect on the binding of neurons 
to substrates that were prepared with mixtures containing 
laminin instead of Ng-CAM; neuronal binding was inhibited 
by  <20%  of control  when  mixtures  containing  approxi- 
mately equal amounts of laminin and the 1D1 or 3F8 pro- 
teoglycans were adsorbed to dishes (data not shown). These 
results suggest that the proteoglycans selectively affect only 
certain adhesive systems. 
Binding of Neurons to Brain Proteoglycans 
The results described above indicate that the brain proteogly- 
cans can interact with CAMs and can inhibit adhesion of 
cells to a CAM. To determine whether cells can bind directly 
to proteoglycans, we used a centrifugation assay that has pre- 
viously been used to demonstrate binding of cells to cytotac- 
Table IlL Effects of mAbs on Attachment of  Neurons to 
Protein-coated Substrates in the Centrifugation Assay 
mAb 
Protein on 
substrate  Control  1  D 1  3F8 
7-d  1D1  2.83  +  0.15  1.13  5:0.18  (60)  2.64  +  0.13  (7) 
Adult  1D1  0.65  +  0.04  0.36  +  0.09  (44)  0.59  +  0.23  (10) 
3F8  1.30  +  0.63  1.43  +  0.09  (0)  >2.5 
Aggrecan  0  0  0 
BSA  0  0  0 
Ng-CAM  >2.5  >2.5  >2.5 
Centrifugation assays were performed as described in the legend to Table II us- 
ing 20 t~g/ml solutions of the indicated proteins. After removing the unbound 
proteins, the wells were washed three times and then incubated for l  h with 
a  1:100 dilution of ascites fluid;  the plates were washed three times and cell 
binding was performed as described in Materials and Methods. Numbers in 
parenthesis represent percent inhibition. 
tin, an extracellular molecule that can inhibit cell adhesion 
and  migration  (Friedlander  et  al.,  1988;  Crossin  et  al., 
1990). Because of its very short duration, the centrifugation 
assay reflects more closely the strength of the initial molecu- 
lar interactions than the gravity assay, which is highly sensi- 
tive to the ability of the immobilized molecule to allow cell 
spreading.  Thus,  proteins  that  bind  to  cells  but  cause  a 
"repulsive" reaction (as appears to be the case with certain 
brain proteoglycans; see above) may demonstrate cell bind- 
ing in the centrifugation assay even though no binding can 
be observed in the gravity assay. In the centrifugation assay, 
cells pelleted to the bottom of U-shaped  wells that were 
treated  with  non-adhesive  molecules.  In  contrast,  cells 
bound to differing degrees to wells that were coated with var- 
ious amounts  of different proteins.  For example,  neurons 
pelleted on BSA-coated wells  and bound tightly to  wells 
treated with Ng-CAM (Fig. 9). 
To determine the relative abilities of different proteins to 
promote neuronal binding in the centrifugation assay,  wells 
were treated  with  various concentrations of the  proteins. 
When proteins were applied at 20 /xg/ml,  neurons bound 
more or less evenly across the wells treated with 7-d ID1 and 
3F8 proteoglycans, and bound to a smaller region in wells 
treated with the adult 1D1 proteoglycan, indicating that cells 
bound more weakly to the adult 1D1 proteoglycan. In con- 
trast, the pattern of neurons observed after centrifugation on 
wells treated with aggrecan was indistinguishable from that 
obtained with BSA, indicating that neurons did not bind to 
aggrecan. The ability of each brain proteoglycan to promote 
binding  was  diminished  when  lower concentrations were 
used (Fig. 9 and Table II). 
To analyze the degree of binding,  we measured the di- 
ameter of the region in which the binding was observed to 
be relatively uniform (for example, see arrow in Fig. 9, adult 
1D1 at 5/zg/ml). The diameter of the binding region was 0 
on non-adhesive substrates and increased to ~2.5 mm on the 
most adhesive substrates (Table II). When the proteoglycans 
were tested at various concentrations, little difference was 
observed between the effectiveness of the 1D1 and 3F8 pro- 
teoglycans from 7-d brain, and the adult form of 1D1  was 
consistently found to be less effective (Table II).  Neurons 
bound strongly to Ng-CAM and they did not bind to aggre- 
can or to BSA in this assay. 
The specificity of neuronal binding to the proteoglycans 
was analyzed using mAbs that specificity recognize the 1D1 
or 3F8 proteoglycans (Table III). The 1D1 mAb partially in- 
hibited neuronal binding to the 1D1 proteoglycan and had no 
effect on binding to the 3F8 proteoglycan suggesting that this 
mAb binds to the 1D1 proteoglycan at or near a region that 
is important for cell binding.  The specificity of binding is 
consistent with previous observations that the 1D1 and 3F8 
mAbs recognize distinct antigenic determinants on different 
brain proteoglycans (Rauch et al.,  1991). The 3F8 antibody 
had no effect on binding to the 1D1 proteoglycan but it in- 
creased the degree of binding to wells coated with the 3F8 
proteoglycan. This increase in binding to wells coated first 
with 3F8 proteoglyean and then with the 3F8 mAb raised the 
possibility that the chick brain ceils could bind directly to 
the 3F8 mAb. In support of  this possible mechanism, prelim- 
inary experiments indicated that chick brain cells bound to 
wells that had been treated only with 3F8 Ig, but not with 
control mAbs. 
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The initial functional characterization of neurocan and the 
3F8 proteoglycan reported here indicates that these brain 
proteoglycans:  (a)  can  inhibit homophilic binding that is 
mediated by N-CAM and Ng-CAM; (b) can inhibit binding 
of neurons to Ng-CAM substrates; and (c) can bind directly 
to neurons. Although it was possible to demonstrate binding 
of neurons to brain proteoglycans using the centrifugation 
assay, the exact physiological relevance of this assay will re- 
quire further investigation. However, this assay has been in- 
strumental in demonstrating that other large multidomain 
proteins such as cytotactin have different regions that possess 
either positive or negative effects  on cell binding (Fried- 
lander et al.,  1988;  Prieto et al.,  1992).  In any case, these 
observations on neurocan and the 3F8 proteoglycan, which 
have been isolated from early postnatal rat brain and show 
dramatic changes in their patterns of expression during brain 
development (Rauch et al., 1991), suggest that proteoglycans 
may affect cell behavior during neural development by inter- 
acting with CAMs. 
Several recent studies have implicated chondroitin sulfate 
and keratan sulfate in cell interactions, based partly on the 
ability of cartilage proteoglycans to inhibit cell adhesion and 
neurite growth on substrates containing either laminin or 
N-CAM (Snow et al.,  1990b,  1991; Perris and Johansson, 
1990).  We have also obtained evidence for interactions be- 
tween brain proteoglycans and N-CAM, but in contrast, we 
found that neurocan and the 3F8 proteoglycan had little or 
no effect on neuronal adhesion to laminin. Moreover, both 
brain  proteoglycans are  potent  inhibitors  of adhesion  to 
Ng-CAM. 
The specific inhibitory effects that we observed with the 
brain proteoglycans can be attributed primarily to the core 
glycoproteins. Although a number of previous studies indi- 
cate the involvement of the glycosaminoglycan portion of 
these molecules (Perris and Johansson,  1990;  Snow et al., 
1990b,  1991; Brittis  et  al.,  1992),  it  appears  that  the 
glycosaminoglycan chains do not contribute significantly to 
the cytotactin/tenascin-binding properties of a chondroitin 
sulfate proteoglycan of embryonic chicken brain (Hoffman et 
al., 1988) and are not required for the effects of chondroitin 
sulfate proteoglycans of brain on neurite outgrowth (Iijima 
et al., 1991; Oohira et al., 1991). Results from studies utiliz- 
ing cartilage proteoglycans, in which only the native pro- 
teoglycan (containing glycosaminoglycan  chains) but not the 
core protein was found to have effects on neurite outgrowth 
or other aspects of cell behavior, might be due merely to a 
high negative charge density. In our studies, for example, 
adhesion of neurons to CAMs was inhibited to a relatively 
small degree (20-35%)  by native (but not chondroitinase- 
treated) aggrecan (Figs. 4 and 7), but these effects may have 
little or no biological significance in view of the fact that 
chondrosarcoma aggrecan contains "~100 chondroitin sul- 
fate chains as compared to the three to four chains in neuro- 
can and the 3F8 proteoglycan. These brain proteoglycans 
differ significantly from aggrecan (in size, primary structure, 
degree and type of substitution with glycosaminoglycans, 
and N- and O-glycosidic oligosaccharides, sulfation, etc.), 
and they probably have different binding specificities. 
Immunocytochemical studies have demonstrated that like 
the total population of soluble chondroitin sulfate proteogly- 
cans of brain whose localization has previously been exam- 
ined using polyclonal antibodies (Aquino et al.,  1984a,  b), 
staining of the  1D1  proteoglycan in 7-d rat cerebellum is 
generally most intense in the prospective white matter and 
absent from the external granule cell layer; in contrast, stain- 
ing of the 3F8 proteoglycan is most intense in the molecular 
layer (Rauch et al.,  1991). A common feature of both pro- 
teoglycans  is  that  they  are  predominantly  expressed  in 
deeper layers of the developing cerebellum and appear to 
form a border between the external granule cell layer and the 
molecular layer. In contrast, N-CAM and Ng-CAM are ex- 
pressed on many cerebellar neurons at the same stages of de- 
velopment and each CAM is distributed in a  pattern that 
crosses the border formed by the proteoglycans (Grumet et 
al., 1984a;  Daniloff  et al., 1986). In the vicinity of this bor- 
der, radially migrating granule cells project parallel fibers 
that contribute to the growth of the molecular layer during 
development, and the granule cells then migrate across the 
molecular layer to reside in the internal granule cell layer 
(Rakic, 1971). The abundance of the 1D1 and 3F8 proteogly- 
cans as well as other adhesion molecules in the molecular 
layer may modulate cell adhesion and provide  signals to 
influence the behavior of the granule cells. For example, the 
inhibitory effects of the proteoglycans may prevent the paral- 
lel fibers from entering the molecular layer, thereby restrict- 
ing them to migrate horizontally. 
Recent studies (Miller, B., A. M.  Sheppard, and A. L. 
Pearlman. 1992. Soc. Neurosci. Abstr.  18:778) showed that 
the 1D1 and 3F8 proteoglycans are also present in the sub- 
plate  region  of the  developing mouse  cerebral  cortex  in 
regions that were previously found to contain chondroitin 
sulfate and fibronectin (Sheppard et al.,  1991). Based on 
correlations between the patterns of protein expression and 
axonal migration during development, it has been suggested 
that these molecules may play a role in defining a destination 
for  migrating  axons  that  form the  cortical  plate,  and  in 
delineating pathways for early axonal extension (Sheppard et 
al.,  1991). 
Our studies raise the possibility that neural proteoglycans 
bind  to  CAMs,  and  further analysis to  explore potential 
mechanism(s) of interaction between these molecules will be 
facilitated by their structural characterization. In 7-d brain, 
the 1D1 proteoglycan consists of a major component contain- 
ing a core glycoprotein with an apparent molecular size on 
SDS-PAGE of 245 kD after enzymatic removal of the three 
~22  kD chondroitin 4- and 6-sulfate chains.  A  1D1  pro- 
teoglycan with a 150-kD core glycoprotein is also present at 
7 d. By 2-3-wk postnatal this becomes the major species, 
and is essentially the only form present in adult brain. Pep- 
tide maps of both core proteins indicated that the 150-kD 
core glycoprotein is a part of the 245-kD core glycoprotein, 
because all peptides generated from it could also be found 
in the larger species (Rauch et al., 1991). The composite se- 
quence of overlapping cDNA clones covering the entire 1D1 
proteoglycan (neurocan) encodes a protein of 1,257 amino 
acids  (Rauch et al.,  1992).  The deduced amino acid se- 
quence revealed a 22 amino acid signal peptide followed by 
an immunoglobulin domain, tandem repeats characteristic 
of the hyaluronic acid-binding region of aggregating pro- 
teoglycans, and an RGDS  sequence.  The COOH-terminal 
portion  (amino  acids  951-1,215)  has  *60%  identity to 
regions in the COOH termini of the fibroblast and cartilage 
proteoglycans, versican  and aggrecan  (Zimmermann and 
Ruoslahti, 1989;  Doege et al.,  1987),  including two EGF- 
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regulatory protein-like sequence. It is noteworthy that cyto- 
tactin/tenascin,  which  contains  many  EGF-like domains, 
can also inhibit cell adhesion (Jones et al.,  1988). The cen- 
tral 595 amino acid portion of neurocan has no homology 
with  other  reported  protein  sequences.  Northern  blots 
demonstrated that a single message of ~7.5 kb was detected 
in  either 4-d  or  adult brain  (but  not in  other rat  tissues 
tested), indicating that the adult form of this proteoglycan is 
derived by in vivo proteolytic processing from the larger spe- 
cies present in early postnatal brain, and that neurocan is a 
new,  and possibly nervous tissue-specific, member of the 
versican/aggrecan proteoglycan family. 
The larger early postnatal  1D1  proteoglycan (neurocan) 
has the ability to form aggregates with hyaluronic acid, and 
a  45-kD  link  protein  which  stabilizes  these  aggregates 
copurifies with the proteoglycan (Rauch et al.,  1991). Since 
link protein binds to the hyaluronic acid-binding domain of 
the proteoglycan core protein as well as to hyaluronic acid, 
it is possible that under appropriate conditions it may serve 
to cross-link neurocan bound to CAMs on the beads,  and 
thereby induce aggregation. This may account for the obser- 
vation that aggregates of CAM-coated Covaspheres were de- 
tected (see Figs. 2 and 3) in the presence of the 7-d form of 
the proteoglycan, but not the adult form (which does not con- 
tain a hyaluronic acid-binding region). The observation that 
the larger form of the  1D1 proteoglycan is more potent in 
binding neurons suggests that in addition to regions in the 
COOH-terminal half of the molecule which may be involved 
in binding to the neural CAMs, the NH2-terminal half may 
contain additional sites important for proteoglycan-cell in- 
teractions. 
In addition to neurocan, we have studied the effects on Ng- 
CAM and N-CAM interactions of the ,,o500-kD 3F8 chon- 
droitin sulfate proteoglycan, which in both early postnatal 
and adult brain shows a core glycoprotein with an apparent 
molecular size of 400 kD after removal of the ,,o28 kD chon- 
droitin sulfate chains. Like neurocan, the 3F8 proteoglycan 
contains ~20% by weight of chondroitin sulfate. Link pro- 
tein is not associated with immunoaflinity purified 3F8 pro- 
teoglycan, which also does not aggregate with hyaluronic 
acid (Rauch et al.,  1991). 
For comparison with these rat brain chondroitin sulfate 
proteoglycans, we have also  examined the effects on Ng- 
CAM and N-CAM interactions of a cartilage chondroitin sul- 
fate proteoglycan (aggrecan) isolated from the transplantable 
Swarm rat chondrosarcoma. This proteoglycan has a 221-kD 
core protein (Doege et al., 1987) to which are attached *100 
chondroitin sulfate chains as well as N- and O-glycosidically 
linked oligosaccharides. Aggrecan also has a hyaluronic acid 
binding  region near its  NH2  terminus  that  can form link 
protein stabilized aggregates with hyaluronic acid. It is un- 
likely  that  the  associated  link  protein  is  responsible  for 
effects of neurocan on CAMs, inasmuch as the chondroitin- 
ase-treated chondrosarcoma aggrecan, which also contains 
link protein (Faltz et al.,  1979; Caterson and Baker, 1979) 
had no effect in our assays, whereas the 3F8 proteoglycan 
which does not contain link protein had strong effects. 
HNK-1 epitopes that are present on both forms of the 1D1 
proteoglycan and on the early postnatal 3F8 proteoglycan 
(Rauch et al.,  1991) are probably not involved in mediating 
interactions with the neural CAMs, insofar as: (a) the chon- 
drosarcoma  proteoglycan  core  protein,  which  contains 
HNK-1 epitopes (Margolis et al., 1987), had no effects in our 
assays; and (b) the adult 3F8 proteoglycan, which is HNK-1 
negative (Rauch et al., 1991), was as effective as the HNK-1- 
positive early postnatal form of this brain proteoglycan (data 
not  shown).  HNK-1  epitopes  are  also  present on  several 
CAMs  including  Ng-CAM  and  N-CAM  (Grumet  et  al., 
1984b; Schachner et al., 1990), and their potential functions 
in cell adhesion need to be explored further (Kiinemund et 
al.,  1988). It is also unlikely that chondroitin sulfate chains 
are involved because chondroitinase-treated proteoglycans 
bound neurons and had strong inhibitory effects. 
Our observations indicate a certain degree of selectivity in 
the effects of neurocan and the 3F8 proteoglycan on Ng- 
CAM and N-CAM, and suggest that they may bind to these 
CAMs. More direct evidence for binding between Ng-CAM 
and neurocan has been obtained in preliminary experiments 
which indicated that green-fluorescing Covaspheres coated 
with Ng-CAM coaggregated specifically with red-fluoresc- 
ing Covaspheres coated with neurocan. The observation that 
the proteoglycans can affect binding mediated both by Ng- 
CAM  and N-CAM  suggests  either that the proteoglycans 
bind to a  common site on Ng-CAM and N-CAM,  or that 
each CAM has a unique binding site for the proteoglycans, 
N-CAM and Ng-CAM share certain structural features in- 
cluding the  presence of HNK-1  epitopes  (Grumet et al., 
1984b),  and both contain Ig-like and  fibronectin-like do- 
mains. However, the degree of amino acid sequence identity 
between chicken N-CAM and Ng-CAM is only 22 % (Bur- 
goon et al., 1991). Although most antibodies distinguish be- 
tween them, they may share certain carbohydrate or protein 
domains that mediate interactions with proteoglycans. It will 
obviously be important to determine the nature of binding 
sites on the CAMs and the proteoglycans that may mediate 
interactions between these molecules, and cDNA constructs 
are being prepared to express specific domains of neurocan 
and Ng-CAM to explore potential interactions. Further in- 
vestigation of the interactions between prote0glycans and 
neural CAMs may thereby provide clues to understanding 
molecular mechanisms of  cell repulsion (Keynes, 1991; Sage 
and Bornstein,  1991). 
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